Member Info for Fruitsnveg

Thanks Brand. It's going to be a busy month.

Such a critical conversation to be a part of.

I can't wait.

I thought you'd like it Doc.Daneeka.

Title: "Don’t be resistant to going antiviral: Could a broad-spectrum inhaled antiviral reduce the incidence of secondary bacterial chest infections?"
Session: Richard Marsden.

"A lot of clever people have invested in this wonder drug over the years based on the amazing science."
Yes Aether. And I suspect they will view Richard's speech at the next AMR Conference very insightful. I am certainly pleased and look forward to knowing more.

"Don’t be resistant to going antiviral: Could a broad-spectrum inhaled antiviral reduce the incidence of secondary bacterial chest infections?" Session: Richard Marsden.

GLA.

Three now dead.

https://www.independent.co.uk/news/health/long-covid-omicron-rise-figures-latest-b2157414.html

Sorry Mani, just posted links as I was in them already.

https://www.telegraph.co.uk/global-health/science-and-disease/mystery-pneumonia-kills-two-infects-six-argentina/

etc.
Our participation in AMR conference should be seen as a positive given these sorts of developments, not downplayed.

https://www.standard.co.uk/news/world/argentina-mystery-pneumonia-death-two-people-covid-b1022386.html

Another few Essex porta-cabin dwelling works of fantasy. It must be getting cramped in there, lol.

lol Gunto.

You just had a social media update on Twitter and a Linkedin update. Both in the last hour.
Stop complaining, it's tedious.

Maybe you could apply for the role Tatty. Your scientific storytelling and lyrical witticisms are wasted here.

Just to add to the playground rhetoric, "A flick and a kick for being so quick" , Doc.Daneeka.

We haven't YET had an RNS. That doesn't mean we won't get one, soon. Brooke signalled 2 SM channels to watch in her response to TP this morning - twitter and company website. If something appears on both it is possible it is RNS worthy, but she can't say that - it would be deemed market abuse to alert shareholders in advance. I'm keeping an open mind here and like many, hoping we know more soon.

I can't say I hold our CEO in the same level of distaste as you Doc.Daneeka, it's quite baffling, but to each their own.

It's interesting. There are just 3 speakers in the 'Therapeutics' category presenting one after the other on Sept 7th. These are the topics:
(1) Meta analysis of RNA data for therapeutic development (American Chemical Society)
(2) Synthetic DNA Technologies Enable Fast and Responsive SARS-CoV-2 Antibody Discovery and Optimization (Twist Bioscience)
(3) TBC ? (Richard Marsden)

Ghia, it seems to be that one of the AMR speakers that previously had no session title, like us, has now submitted (so not an Admin error I'm thinking?). It's interesting; Katie Boland, CEO of Adaptive Biotechnologies will speak about "Turning large-scale immune repertoire data into insights in infectious disease". I am excited to know the topic of Richard Marsden's session.

Worth noting that Strive, although touted here a lot, is not the only PT available to Synairgen. All eggs do not reside in one basket, but I guess most investors know this already.